GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: JNJ-78278343 | JNJ78278343
Compound class:
Antibody
Comment: Pasritamig (JNJ-78278343) is a bispecific kallikrein related peptidase 2 (KLK2)/CD3e monoclonal antibody. It acts as a T-cell engager targeting KLK2 on tumour cells.
The peptide sequences for the heavy and light chains of pasritamig's KLK2 binding domain are claimed in patent US11965024B2 [1] and are a component of the antibody named KL2B30. The anti-cD3e component is claimed in patent US11827708B2 [2]. |
| No information available. |
Summary of Clinical Use  |
| Pasritamig (JNJ-78278343) was progressed to clinical studies to evaluate its safety and efficacy as an anti-tumour agent, notably as a late-line treatment for metastatic castration-resistant prostate cancer (mCRPC). Anti-tumour efficacy in phase 1 confirmed KLK2 as a molecular target in prostate cancer. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07164443 | A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 Interventional | Janssen Research & Development, LLC | ||
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 Interventional | Janssen Research & Development, LLC | ||
| NCT04898634 | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | Phase 1 Interventional | Janssen Research & Development, LLC | 3 | |
